Literature DB >> 19702567

Aptamers as innovative diagnostic and therapeutic agents in the central nervous system.

Vittorio de Franciscis1, Carla Lucia Esposito, Silvia Catuogno, Luciano Cellai, Laura Cerchia.   

Abstract

Aptamers are short non-naturally occurring single stranded DNA or RNA able to bind tightly, due to their specific three-dimensional shapes, to a multitude of targets ranging from small chemical compounds to cells and tissues. Since their first discovery, aptamers became a valuable research tool and show great application to fundamental research, drug selection and clinical diagnosis and therapy. Thanks to their unique characteristics (low size, good affinity for the target, no immunogenicity, chemical structures that can be easily modified to improve their in vivo applications), aptamers may represent a valid alternative to antibodies particularly for the treatment of neurological disorders that urgently needs modalities for drug delivery through the blood brain barrier. Aptamers have excellent potential as reagents for the targeted delivery of active drug substances, either through direct conjugation to the aptamer, or through their encapsulation in aptamer-coated vesicles. We will review here the recent and innovative methods that have been developed and the possible applications of aptamers as inhibitors or tracers in neurological disorders and brain cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19702567     DOI: 10.2174/187152709789542023

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  6 in total

1.  Aptamer identification of brain tumor-initiating cells.

Authors:  Youngmi Kim; Qiulian Wu; Petra Hamerlik; Masahiro Hitomi; Andrew E Sloan; Gene H Barnett; Robert J Weil; Patrick Leahy; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Res       Date:  2013-06-24       Impact factor: 12.701

2.  Diagnosing and Treating Nervous System Disorders by Targeting Novel Classes of Non-coding RNAs.

Authors:  Irfan A Qureshi; Mark F Mehler
Journal:  Int Drug Discov       Date:  2011 Jun-Jul

3.  Intra-accumbens injection of a dopamine aptamer abates MK-801-induced cognitive dysfunction in a model of schizophrenia.

Authors:  Matthew R Holahan; Dan Madularu; Erin M McConnell; Ryan Walsh; Maria C DeRosa
Journal:  PLoS One       Date:  2011-07-13       Impact factor: 3.240

4.  Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model.

Authors:  Huiyu Liang; Yusheng Shi; Zhewen Kou; Yonghua Peng; Wenjun Chen; Xiaowen Li; Shuji Li; Ying Wang; Fang Wang; Xingmei Zhang
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

Review 5.  NADPH oxidase in brain injury and neurodegenerative disorders.

Authors:  Merry W Ma; Jing Wang; Quanguang Zhang; Ruimin Wang; Krishnan M Dhandapani; Ratna K Vadlamudi; Darrell W Brann
Journal:  Mol Neurodegener       Date:  2017-01-17       Impact factor: 14.195

6.  Current progress of RNA aptamer-based therapeutics.

Authors:  Jiehua Zhou; Maggie L Bobbin; John C Burnett; John J Rossi
Journal:  Front Genet       Date:  2012-11-02       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.